Andrew G. Stephen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Andrew G. Stephen has a total of 241 co-authors. Here are the top co-authors by number of shared publications:
- Dhirendra K. Simanshu
NCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, USA
60 shared publications - Dwight V. Nissley
NCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, USA
51 shared publications - Frank McCormick
University of California, San Francisco 9 Helen Diller Family Comprehensive Cancer Center San Francisco, California
51 shared publications - Patrick A. Alexander
NCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland
47 shared publications - Albert H. Chan
Frederick National Laboratory for Cancer Research 2 NCI RAS Initiative, Cancer Research Technology Program Leidos Biomedical Research, Inc., Frederick, Maryland
46 shared publications - Anna E. Maciag
NCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, USA
46 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
Supplementary Figure S2 shows the sensorgrams curves used to calculate the binding kinetics of BBO-11818 to four KRAS variants and wild-type HRAS and NRAS in their GDP- or GppNHp-bound forms in a Surface Plasmon Resonance (SPR) assay.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
Supplementary Figure S2 shows the sensorgrams curves used to calculate the binding kinetics of BBO-11818 to four KRAS variants and wild-type HRAS and NRAS in their GDP- or GppNHp-bound forms in a Surface Plasmon Resonance (SPR) assay.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
Supplementary Figure S1 shows the sensorgrams curves used to calculate the binding kinetics of Compound 2 to three KRAS variants in their GDP- or GppNHp-bound forms in a Surface Plasmon Resonance (SPR) assay.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
Supplementary Figure S1 shows the sensorgrams curves used to calculate the binding kinetics of Compound 2 to three KRAS variants in their GDP- or GppNHp-bound forms in a Surface Plasmon Resonance (SPR) assay.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
Supplementary Table S2 shows individual EC50 data for the inhibition of ERK phosphorylation in a panel of KRAS-mutant cell lines treated with BBO-11818.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
Supplementary Table S2 shows individual EC50 data for the inhibition of ERK phosphorylation in a panel of KRAS-mutant cell lines treated with BBO-11818.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C
Supplementary Table S1 summarizes the crystallography data for BBO-8520 bound to GMPPNP- and GDP-bound KRAS G12C
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C
Supplementary Table S1 summarizes the crystallography data for BBO-8520 bound to GMPPNP- and GDP-bound KRAS G12C
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
Supplementary Figure S3 shows the binding of BBO-11818 bound to KRASG12D and HRASG12D/Q95H, detailing key interactions in the binding pocket through electron density contours and crystal structure models.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
Supplementary Figure S3 shows the binding of BBO-11818 bound to KRASG12D and HRASG12D/Q95H, detailing key interactions in the binding pocket through electron density contours and crystal structure models.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
Supplementary Table S1 shows detailed crystallographic data collection and refinement statistics for the interaction of KRASG12D and BBO-11818 in its GDP or GppNHp-bound forms, or for the interaction of HRASG12D/Q95H and BBO-11818 in its GppNHp-bound form.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
Supplementary Table S1 shows detailed crystallographic data collection and refinement statistics for the interaction of KRASG12D and BBO-11818 in its GDP or GppNHp-bound forms, or for the interaction of HRASG12D/Q95H and BBO-11818 in its GppNHp-bound form.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
Supplementary Figure S6 shows densitometry analysis for pERK and pAKT in a western blot experiment in KRASG12D and KRASG12D/A59G cells treated with BBO-11818 or DMSO.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
Supplementary Figure S6 shows densitometry analysis for pERK and pAKT in a western blot experiment in KRASG12D and KRASG12D/A59G cells treated with BBO-11818 or DMSO.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
Supplementary Figure S4 shows the binding differences of BBO-11818 and BBO-8520 to KRASG12D and KRASG12C, respectively, in the GDP- or GppNHp-bound states, in a crystal structure model. Additionally, it shows in silico predicted interactions of BBO-11818 to different KRAS variants, based on the crystal structure model of BBO-11818 to KRASG12D.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
Supplementary Figure S4 shows the binding differences of BBO-11818 and BBO-8520 to KRASG12D and KRASG12C, respectively, in the GDP- or GppNHp-bound states, in a crystal structure model. Additionally, it shows in silico predicted interactions of BBO-11818 to different KRAS variants, based on the crystal structure model of BBO-11818 to KRASG12D.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
Supplementary Table S3 shows individual EC50 data for the inhibition of cell viability in a panel of KRAS-mutant cell lines treated with BBO-11818.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
Supplementary Table S3 shows individual EC50 data for the inhibition of cell viability in a panel of KRAS-mutant cell lines treated with BBO-11818.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C
Supplementary Figure S4 summarizes cysteine profiling, RNA-seq and kinomescan studies demonstrating that BBO-8520 is selective for KRAS G12C and MAPK inhibition.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C
Supplementary Figure S4 summarizes cysteine profiling, RNA-seq and kinomescan studies demonstrating that BBO-8520 is selective for KRAS G12C and MAPK inhibition.